Skip to main content

Cytosorbents Corp

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

CTSO$5.83+21.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

​ ​ ​Page
PART I. FINANCIAL INFORMATION · ​
​​​
Item 1. Financial Statements​3
​
Condensed Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 2025​3
​​​
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2026 and 2025 (unaudited)​4
​​​
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Three and Six Months Ended June 30, 2026 and 2025 (unaudited)​5
​​​
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025 (unaudited)​6
​
Notes to Condensed Consolidated Financial Statements (unaudited)​7
​
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations​25
​
Item 3. Quantitative and Qualitative Disclosures About Market Risk​33
​
Item 4. Controls and Procedures​34
​
PART II. OTHER INFORMATION​
​
Item 1. Legal Proceedings​36
​
Item 1A. Risk Factors​36
​
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds​36
​
Item 3. Defaults Upon Senior Securities​36
​
Item 4. Mine Safety Disclosures​36
​
Item 5. Other Information​37
​
Item 6. Exhibits​37
​​​
Signatures​38

This Report includes our trademarks and trade names, such as “CytoSorb,” “CytoSorb XL,” “ECOS-300CY,” “BetaSorb,” “ContrastSorb,” “DrugSorb,” “DrugSorb-ATR,” “HemoDefend-RBC,” “HemoDefend-BGA,” “K+ontrol,” “VetResQ,” “PuriFi,” and “HotSwap,” which are protected under applicable intellectual property laws and are the property of CytoSorbents Corporation and its subsidiaries. This Report also contains the trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Report may appear without the ™, ®, or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by these other parties.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.